European Healthcare Expenditure on Pharmaceuticals and Medical Non-Durable Goods by Compulsory Contributory Health Insurance Schemes and Compulsory Medical Saving Accounts (CMSA) Share by Country (Million Euros)

In 2023, Germany led European healthcare expenditure on pharmaceuticals and medical non-durable goods, registering 43.74 million euros, followed by France at 28.15 million euros. Markets like Switzerland and Croatia showed significant growth with 6.55% year-on-year increases. Lithuania had the highest increase at 15.04%, while Greece and Portugal saw declines of 5.25% and 27.3%, respectively. For long-term growth, Slovenia and Bosnia and Herzegovina exhibited strong positive trends, with Slovenia showing a 7.25% increase. The average annual growth over five years suggests continued variability in national investment strategies.

Future trends to observe include the potential for increased investment in countries showing current strong growth rates like Lithuania, as well as the possibility of policy adaptations in countries facing declines such as Portugal and Greece. Monitoring regulatory changes and healthcare reforms across Europe will be critical for assessing long-term expenditure trends. Advancements in pharmaceutical technology and evolving insurance models could also impact spending patterns significantly.